RT Book, Section
A1 Carabello, Blase A.
A2 Fuster, Valentin
A2 Harrington, Robert A.
A2 Narula, Jagat
A2 Eapen, Zubin J.
SR Print(0)
ID 1161731990
T1 MANAGEMENT OF MIXED VALVULAR HEART DISEASE
T2 Hurst's The Heart, 14e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9780071843249
LK accesscardiology.mhmedical.com/content.aspx?aid=1161731990
RD 2024/04/20
AB The  2006  American  College  of  Cardiology  (ACC)/American  Heart  Association  (AHA)  guidelines  for  the  treatment  of  valvular  heart  disease  (VHD)  were  notable  for  the  paucity  (0.3%)  of  the  recommendations  supported  by  a  level  of  evidence  A—that  is,  evidence  supported  by  two  or  more  randomized  controlled  trials  (RCTs).1  Although  several  RCTs  have  been  published  since  then  and  the  evidence  level  supporting  the  2014  guidelines  improved  markedly,2  there  are  no  RCTs  and  indeed  only  limited  data-driving  management  decisions  in  mixed  VHD.  In  a  230-page  document,  the  current  guideline  devotes  scarcely  two  pages  to  the  topic.  The  following  chapter  will  summarize  some  of  the  modest  data  that  are  available.